CAP Chemotherapy Cycle Recommendation
The evidence does not support the use of CAP (cyclophosphamide, doxorubicin, and cisplatin) chemotherapy for any indication where it would be considered standard of care. The provided guidelines and FDA labeling do not recommend CAP as a preferred regimen for any cancer type.
Context and Evidence Analysis
What the Guidelines Actually Recommend
The NCCN guidelines 1 for ovarian cancer—the only malignancy where CAP has been historically studied—do not list CAP as a recommended regimen. Instead, they recommend:
- Paclitaxel/carboplatin combinations (Category 1) for 6 cycles
- BEP (bleomycin, etoposide, cisplatin) for malignant germ cell tumors: 3 cycles for good risk, 4 cycles for poor risk 1
The 2025 ASCO guideline for neoadjuvant ovarian cancer 2 recommends ≤4 cycles of NACT before interval cytoreductive surgery, with a total of 6 cycles (NACT plus post-ICS), but again does not mention CAP.
FDA Labeling for Cisplatin
The FDA label for cisplatin 3 specifies dosing for metastatic ovarian tumors in combination with cyclophosphamide (not the full CAP regimen):
- Cisplatin 75-100 mg/m² IV once every 4 weeks
- Cyclophosphamide 600 mg/m² IV once every 4 weeks
This is a 2-drug regimen (CP), not CAP. The FDA label does not recommend adding doxorubicin.
Research Evidence on CAP
The research studies reveal why CAP is not recommended:
Ovarian Cancer:
- A 1992 randomized trial 4 comparing 5 vs 10 cycles of CAP found no survival difference (P=0.41), with 5 cycles being less toxic
- Complete response rates were only 34-35% at second-look laparotomy
- The study concluded CAP5 is preferable to CAP10 due to equal efficacy but less toxicity
Other Malignancies:
- Lung cancer studies 5, 6 showed no survival benefit for CAP vs no treatment in stage I NSCLC
- Only 53% of patients completed all 4 cycles due to poor compliance and toxicity
- The authors concluded CAP "should not be recommended" for resected early-stage lung cancer
Clinical Decision Algorithm
If You Are Considering CAP:
Stop and reconsider the indication
- CAP is not a guideline-recommended regimen for any cancer type in 2025
- Modern platinum-taxane doublets have replaced CAP in ovarian cancer
For ovarian cancer specifically:
If CAP must be used (historical protocol or resource-limited setting):
- Based on the only positive comparative data: 5 cycles maximum 4
- Dosing: Cyclophosphamide 600 mg/m², doxorubicin 40 mg/m², cisplatin 100 mg/m² every 4 weeks
- Expect only 53% completion rate and significant toxicity
Critical Caveats
- Myelosuppression is severe: Grade 3-4 leukopenia in 69% of patients, with frequent nadir fever requiring hospitalization 4
- Renal toxicity: Median creatinine elevation is significant 4
- Peripheral neuropathy is common and cumulative 4
- Poor compliance: Only 53-57% of patients complete planned therapy 5, 6
- Cardiac toxicity: Doxorubicin adds cumulative cardiotoxicity risk without proven benefit over CP alone
Bottom Line
Do not use CAP. If treating ovarian cancer, use paclitaxel/carboplatin for 6 cycles 1. If you inherited a patient on CAP from a historical protocol, the evidence supports 5 cycles maximum 4, but strongly consider switching to guideline-concordant therapy.